Improving life health for people affected by CNS disorders
Autobahn Therapeutics is a clinical-stage biotechnology company developing next-generation medications for central nervous system (CNS) disorders, including neuropsychiatric and neuroimmunologic conditions. Its lead candidate ABX-002 is a thyroid hormone receptor beta agonist in Phase 2 trials for bipolar depression, guided by a brain-targeting chemistry platform and biomarker-driven development.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2024
Sep 2022
Jun 2020
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
